The research, which was published in the Journal of Telemedicine and Telecare, involved 39 patients who have COPD and had at least one hospitalization or emergency room visit during the year prior to enrollment.
Anthem Medicare Advantage members in Ohio with chronic obstructive pulmonary disease will be able to use Propeller's mobile app and its sensors that attach to inhalers.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The move is designed to help the New Zealand device company accelerate distribution of its sensor following the opening of a U.S. office in San Mateo, California, earlier this year.
Propeller and GlaxoSmithKline announced a joint development agreement less than a year ago.
Nephron Pharmaceuticals, a maker of generic respiratory meds, has raised $75 million in debt financing, according to a regulatory filing. The company is based in Orlando, Florida and employs about 500. It announced two years ago that it would expand its operations, building out an expansive South Carolina site with a $313 million investment. The company’s […]